Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?

被引：0
|
作者：
Helmut Oettle
Andreas Hilbig
机构：
[1] Berlin,H Oettle is an Associate Professor and A Hilbig is a Clinical Research Fellow in the Department of Medical Oncology and Hematology at the Charité School of Medicine
[2] Germany.,undefined
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：686 / 687
页数：1
相关论文
共 50 条
  • [1] Does the addition of erlotinib to gemcitabine improve outcome in patients with advanced pancreatic cancer?
    Oettle, H.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (12): : 686 - 687
  • [2] The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
    Khalil, Mohamed A.
    Qiao, Wei
    Carlson, Peter
    George, Binsah
    Javle, Milind
    Overman, Michael
    Varadhachary, Gauri
    Wolff, Robert A.
    Abbruzzese, James L.
    Fogelman, David R.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1375 - 1383
  • [3] The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer
    Mohamed A. Khalil
    Wei Qiao
    Peter Carlson
    Binsah George
    Milind Javle
    Michael Overman
    Gauri Varadhachary
    Robert A. Wolff
    James L. Abbruzzese
    David R. Fogelman
    Investigational New Drugs, 2013, 31 : 1375 - 1383
  • [4] The Addition of Erlotinib to Gemcitabine and Cisplatin Does Not Appear to Improve Median Survival In Metastatic Pancreatic Cancer
    Carlson, P.
    Fogelman, D.
    Kelley, B.
    Qiao, W.
    Javle, M.
    Overman, M.
    Varadhachary, G.
    Wolff, R.
    Abbruzzese, J.
    PANCREAS, 2010, 39 (08) : 1313 - 1313
  • [5] The biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancer
    Irie, Kuniyasu
    Ueno, Makoto
    Kobayashi, Satoshi
    Gouda, Yoshihiro
    Ohkawa, Shinichi
    Manabu, Morimoto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] GEMCITABINE AND ERLOTINIB IN PATIENTS WITH ADVANCED PANCREATIC CANCER: RETROSPECTIVE SINGLE INSTITUTION EXPERIENCE
    Sakai, D.
    Satoh, T.
    Kudo, T.
    Hama, N.
    Wada, H.
    Kobayashi, S.
    Eguchi, H.
    Nagano, H.
    Doki, Y.
    Mori, M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [7] A phase I study of erlotinib, bevacizumab and gemcitabine in patients with advanced pancreatic cancer
    Gomez-Martin, C.
    Camara, J. C.
    Cortes, H.
    Jara, C.
    Gravalos, C.
    Rubio, B.
    Amador, M. L.
    Hidalgo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer
    Kim, Eunji
    Kim, Kyubo
    Chie, Eui Kyu
    Oh, Do-Youn
    Kim, Yong Tae
    JOURNAL OF BUON, 2017, 22 (04): : 1046 - 1052
  • [9] A PILOT TRIAL OF GEMCITABINE IN COMBINATION WITH CAPECITABINE OR ERLOTINIB COMPARED TO GEMCITABINE ALONE IN PATIENTS WITH ADVANCED PANCREATIC CANCER
    Cho, J. Y.
    Lim, J. Y.
    Lee, S. J.
    Lee, D. K.
    Park, J. S.
    Yoon, D. S.
    Min, Y. H.
    ANNALS OF ONCOLOGY, 2012, 23 : 240 - 240
  • [10] EFFICACY AND POSSIBLE BIOMARKER OF GEMCITABINE AND ERLOTINIB FOR ADVANCED PANCREATIC CANCER
    Takahashi, Hideaki
    Kuwahara, Akiko
    Okuyama, Hiroyuki
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Shinohara, Akira
    Kobayashi, Misaki
    Okusaka, Takuji
    Ikeda, Masafumi
    ANNALS OF ONCOLOGY, 2014, 25
12345